Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage

Ding, Chenyu; Cai, Han-Pei; Ge, Hongliang; Yu, Long; Lin, Yuanxiang; Kang, Dezhi

doi:10.3171/2018.8.jns181839

Cited by 8 publications

(7 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Quantifying plasma Lp-PLA 2 is useful for identifying plaque instability, acute coronary syndrome, and other cardiovascular diseases [98,99,100]. Moreover, Lp-PLA 2 is a predictor for incident ischemic stroke severity, early neurological deterioration in patients with acute ischemic stroke, and delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage [101,102,103]. However, inhibiting Lp-PLA 2 by darapladib, a synthetic specific small molecular weight inhibitor of platelet-activating factor-acetylhydrolase (PAF-AH), did not yield promising results in clinical trials [104,105].…”

Section: Mechanisms For Increased Circulating Lysophosphatidylcholmentioning

confidence: 99%

An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases

Law

Chan

Marathe

et al. 2019

IJMS

495

379

View full text Add to dashboard Cite

Lysophosphatidylcholine (LPC) is increasingly recognized as a key marker/factor positively associated with cardiovascular and neurodegenerative diseases. However, findings from recent clinical lipidomic studies of LPC have been controversial. A key issue is the complexity of the enzymatic cascade involved in LPC metabolism. Here, we address the coordination of these enzymes and the derangement that may disrupt LPC homeostasis, leading to metabolic disorders. LPC is mainly derived from the turnover of phosphatidylcholine (PC) in the circulation by phospholipase A2 (PLA2). In the presence of Acyl-CoA, lysophosphatidylcholine acyltransferase (LPCAT) converts LPC to PC, which rapidly gets recycled by the Lands cycle. However, overexpression or enhanced activity of PLA2 increases the LPC content in modified low-density lipoprotein (LDL) and oxidized LDL, which play significant roles in the development of atherosclerotic plaques and endothelial dysfunction. The intracellular enzyme LPCAT cannot directly remove LPC from circulation. Hydrolysis of LPC by autotaxin, an enzyme with lysophospholipase D activity, generates lysophosphatidic acid, which is highly associated with cancers. Although enzymes with lysophospholipase A1 activity could theoretically degrade LPC into harmless metabolites, they have not been found in the circulation. In conclusion, understanding enzyme kinetics and LPC metabolism may help identify novel therapeutic targets in LPC-associated diseases.

show abstract

Section: Mechanisms For Increased Circulating Lysophosphatidylcholmentioning

confidence: 99%

An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases

Law

Chan

Marathe

et al. 2019

IJMS

495

379

View full text Add to dashboard Cite

show abstract

“…Several studies have mentioned that biochemical indicators could serve as predictive factors of the prognosis in patients with aSAH, such as lipoprotein‐associated phospholipase A2, high‐sensitivity C‐reactive protein 12,13 . However, the change of a single indicator may not provide strong and sufficient clinical evidences for clinicians to diagnose the diseases.…”

Section: Introductionmentioning

confidence: 99%

“…Several studies have mentioned that biochemical indicators could serve as predictive factors of the prognosis in patients with aSAH, such as lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein. 12,13 However, the change of a single indicator may not provide strong and sufficient clinical evidences for clinicians to diagnose the diseases. The predictive models are a derivative tool in statistics which are useful to predict the prognostic outcomes on the basis of the pooled evaluations of physical, laboratory, and radiologic examinations.…”

mentioning

confidence: 99%

Development and validation of a predictive model for the prognosis in aneurysmal subarachnoid hemorrhage

Zhang

et al. 2020

Clinical Laboratory Analysis

View full text Add to dashboard Cite

Aneurysmal subarachnoid hemorrhage (aSAH) is an acute cerebrovascular disease that seriously damages the central nervous system and simultaneously exerts pathophysiological effects on multiple organs of the body, with high mortality and morbidity. 1,2 Approximately onethird of the survivors suffer from severe disability and functional dependency. 3 Rebleeding is a major early complication of aSAH with the incidence of 6%-23%, which most occurs within 72 hours of onset. 4,5 Previous studies reported that the mortality was 50%-60% in the presence of rebleeding. 4-6 To date, craniotomy clipping and endovascular embolization serve as main treatments for aSAH to prevent and treat complications such as rebleeding, vasospasm and hydrocephalus, and to reduce the occurrences of deaths and disabilities. 7-11 Although improvements in intensive care and treatments in recent years, the prognosis is still a frequent concern for aSAH. To the best of our knowledge,

show abstract

“…Also, Lp-PLA2 may be a prognostic factor for ischemic stroke severity, as it was observed that patients with high Lp-PLA2 levels had more severe symptoms after stroke and earlier neurological deterioration [129]. Lp-PLA2 in the early stages of aneurysmal subarachnoid hemorrhage might be a new predictive biomarker for the occurrence of delayed cerebral ischemia [130].…”

Section: Lysophosphatidylcholinementioning

confidence: 99%

“…In addition to its diagnostic value in ACS, copeptin proved to be efficient as a prognostic biomarker, being correlated with the 1-year mortality and major complications after an acute coronary event [134]. Studies showed that copeptin levels were correlated with the size of the myocardial infarction and the degree of left ventricular dysfunction and ventricular remodeling [130,135]. Also, in patients with heart failure, copeptin was identified as a valuable prognosis biomarker, being able to predict adverse outcomes and mortality [128,129].…”

Section: Copeptinmentioning

confidence: 99%

Biomarkers Utility: At the Borderline between Cardiology and Neurology

Ion

Stafie

Mitu

et al. 2021

JCDD

View full text Add to dashboard Cite

Biomarkers are important diagnostic and prognostic tools as they provide results in a short time while still being an inexpensive, reproducible and accessible method. Their well-known benefits have placed them at the forefront of research in recent years, with new and innovative discoveries being implemented. Cardiovascular and neurological diseases often share common risk factors and pathological pathways which may play an important role in the use and interpretation of biomarkers’ values. Among the biomarkers used extensively in clinical practice in cardiology, hs-TroponinT, CK-MB and NTproBNP have been shown to be strongly influenced by multiple neurological conditions. Newer ones such as galectin-3, lysophosphatidylcholine, copeptin, sST2, S100B, myeloperoxidase and GDF-15 have been extensively studied in recent years as alternatives with an increased sensitivity for cardiovascular diseases, but also with significant results in the field of neurology. Thus, given their low specificity, the values interpretation must be correlated with the clinical judgment and other available investigations.

show abstract

Assessment of lipoprotein-associated phospholipase A2 level and its changes in the early stages as predictors of delayed cerebral ischemia in patients with aneurysmal subarachnoid hemorrhage

Cited by 8 publications

References 31 publications

An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases

An Updated Review of Lysophosphatidylcholine Metabolism in Human Diseases

Development and validation of a predictive model for the prognosis in aneurysmal subarachnoid hemorrhage

Biomarkers Utility: At the Borderline between Cardiology and Neurology

Contact Info

Product

Resources

About